Herceptin ® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis

This study will evaluate survival trends associated with originator trastuzumab in patients with HER2+ early breast cancer. As originator trastuzumab has been researched in both clinical and real-world settings for close to 20  years, a cumulative NMA is likely to show improved precision around the parameter estimates for trastuzumab now compared with when the drug was initially launched in the USA in 1998. A better understanding of the evolution of publicly available comparative evidence for originator trastuzumab wi ll further inform treatment for patients with HER2+ early breast cancer, providing benefit to patients, health professionals, and researchers.Systematic review registrationPROSPERO CRD42017055763https://www.crd.york.ac.uk/PROSPERO
Source: Systematic Reviews - Category: International Medicine & Public Health Source Type: research